U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Suppression of the T-dependent Antibody Response Following Oral Exposure to Selected Polycyclic Aromatic Compounds in B6C3F1/N Mice

Victor J. Johnson1, Cynthia V. Rider2, Michael I. Luster1, Cynthia J. Willson3, Shawn Harris4, Esra Mutlu2, Veronica Godfrey2, Suramya Waidyanatha2, Billie Stiffler5, Brian Burback5, Gary R. Burleson1, Dori R. Germolec2

1Burleson Research Technologies, Inc. Morrisville, NC, USA
2Division of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
3Integrated Laboratory Systems, LLC, An Inotiv Company, Morrisville, NC, USA
4DLH, LLC., Bethesda, MD, USA
5Battelle, Columbus, OH, USA

DOI: https://doi.org/10.22427/NTP-DATA-500-005-004-000-4

Publication

Abstract

The ability of polycyclic aromatic compounds (PACs), most notably benzo(a)pyrene [B(a)P], to suppress antibody responses in experimental animals is well documented. Very little information, however, is available on the immunotoxicity of related PACs despite their widespread presence in the environment. Additionally, there are several weaknesses in existing immunotoxicity databases for PACs in experimental animals, limiting their applicability in quantitative risk assessment. Careful characterization of strong positive and clear negative PACs is needed in order to lay the foundation for generating robust immunotoxicity data for structurally diverse PACs that have not yet been evaluated. In the current study, adult B6C3F1/N female mice were treated daily for 28 consecutive days by oral administration of B(a)P to provide dose levels ranging between 2 and 150 mg/kg body weight/day. In addition, phenanthrene and pyrene, non-carcinogenic PACs, were tested at dose ranges between 12.5 and 800 mg/kg body weight/day and 3.1 and 200 mg/kg body weight/day, respectively. B(a)P exposure resulted in significant decreases in lymphoid organ weights, immune cell populations in the spleen and T-dependent antibody responses (TDAR). The most sensitive indicator for immunotoxicity from B(a)P treatment was suppression of antibody responses, where an ~75% decrease occurred at a dose level of 9 mg/kg body weight/day and ~32% decrease at the lowest tested dose of 2 mg/kg body weight/day. Antibody suppression was associated with significant immune cell loss in the spleen; however, it was clear that the suppression of the TDAR was more sensitive than cell loss indicating that cell function impairments were involved. Phenanthrene treatment also resulted in suppression of the antibody response but only at dose levels ≥50 mg/kg body weight/day without significant effects on other parameters, while pyrene showed no significant immune effects. These studies lay the foundation for evaluating diverse PACs with a range of immunotoxicological potencies.

Study Data

Study Tables - Mouse Immunotoxicity Benzo(a)pyrene (28 day)

Study Tables - Mouse Immunotoxicity Phenanthrene (28 day)

Study Tables - Mouse Immunotoxicity Pyrene (28 Day)